Literature DB >> 31213412

Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.

Gustavo Schvartsman1, Andre P C D Carneiro2, Renee Z Filippi2, Priya Rao3, Pavlos Msaouel4.   

Abstract

Entities:  

Keywords:  CTLA-4; Checkpoint inhibitors; Immunotherapy; Kidney cancer; PD-1

Mesh：

Substances：

Year:  2019        PMID： 31213412     DOI： 10.1016/j.clgc.2019.05.023

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  4 in total

1.  Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.

Authors:  Tomoki Okada; Shuzo Hamamoto; Toshiki Etani; Taku Naiki; Yasuhito Sue; Rika Banno; Kenji Yamada; Takeshi Sakakura; Takahiro Yasui
Journal:  Int Cancer Conf J       Date:  2020-03-13

Review 2.  Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

Authors:  Panagiotis Zoumpourlis; Giannicola Genovese; Nizar M Tannir; Pavlos Msaouel
Journal:  Clin Genitourin Cancer       Date:  2020-12-02       Impact factor: 2.872

3.  Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Authors:  Leah K Shaw; Andrew J Wiele; Kanishka Sircar; Christopher G Wood; Pavlos Msaouel
Journal:  Cancer Treat Res Commun       Date:  2021-03-10

Review 4.  Sarcomatoid renal cell carcinoma: biology, natural history and management.

Authors:  Jose A Karam; A Ari Hakimi; Kyle A Blum; Sounak Gupta; Satish K Tickoo; Timothy A Chan; Paul Russo; Robert J Motzer
Journal:  Nat Rev Urol       Date:  2020-10-13       Impact factor: 14.432
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.